{"prompt": "['Product: MK-3475', '36', 'Protocol/Amendment No.: 604-09', 'Have no evidence of new or enlarging brain metastases confirmed by', 'post-treatment repeat brain imaging (using the same modality) performed at least', '3 weeks after pre-treatment brain imaging, and', 'Are neurologically stable without the need for steroids for at least 7 days before', 'first dose of trial treatment as per local site assessment.', '5. Has had major surgery within 3 weeks prior to receiving the first dose of trial', 'treatment or has not recovered adequately from toxicity and/or complications from an', 'intervention prior to receiving the first dose of study treatment.', '6. Has a history of non-infectious pneumonitis that required steroids or has current', 'pneumonitis.', '7. Has a known history of interstitial lung disease.', '8. Has a known additional malignancy that is progressing or requires active treatment.', 'Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with', 'curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin,', 'in situ cervical cancer, or in situ breast cancer that has undergone potentially curative', 'therapy.', '9. Has active autoimmune disease that has required systemic treatment in the past', '2 years (ie, with use of disease-modifying agents, corticosteroids, or', 'immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or', 'physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)', 'is not considered a form of systemic treatment.', '10. Has a known history of, or active, neurologic paraneoplastic syndrome.', '11. Has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal', 'obstruction, and/or abdominal carcinomatosis.', '12. Has a history of a severe hypersensitivity reaction to treatment with another', 'monoclonal antibody.', '13. Is taking chronic systemic steroids (in doses exceeding 10 mg daily of prednisone', 'equivalent) within 7 days prior to the first dose of trial treatment.', 'Note: Subjects with asthma or chronic obstructive pulmonary disease that require', 'intermittent use of bronchodilators, inhaled steroids, or local steroid injections would', 'not be excluded from the study.', '14. Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive', 'therapy within 7 days prior to the first dose of trial treatment.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '37', 'Protocol/Amendment No.: 604-09', '15. Has received a live vaccine within 30 days prior to the first dose of trial drug.', 'Examples of live vaccines include, but are not limited to, the following: measles,', 'mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus', 'Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for', 'injection are generally killed virus vaccines and are allowed; however, intranasal', 'influenza vaccines (eg, FluMist\u00ae) are live attenuated vaccines and are not allowed.', '16. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or', 'with an agent directed to another co-inhibitory T-cell receptor (ie, CTLA-4, OX-40,', 'CD137) or has previously participated in a Merk pembrolizumab (MK-3475) clinical', 'trial.', '17.', 'Has severe hypersensitivity (Grade >3) to pembrolizumab and/or any of its', 'excipients.', '18. Has an active infection requiring systemic therapy.', '19. Has a known history of HIV infection. No HIV testing is required unless mandated by', 'local health authority.', '20. Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]', 'reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is', 'detected) infection.', 'Note: No testing for hepatitis B and hepatitis C is required unless mandated by local', 'health authority.', '21. Has a known history of active TB (Bacillus Tuberculosis).', '22. Has a history or current evidence of any condition, therapy, or laboratory abnormality', \"that might confound the results of the study, interfere with the subject's participation\", 'for the full duration of the study, or is not in the best interest of the subject to', 'participate, in the opinion of the treating investigator.', '23. Has known psychiatric or substance abuse disorders that would interfere with', 'cooperation with the requirements of the trial.', '24. Has symptomatic ascites or pleural effusion. A subject who is clinically stable', 'following treatment for these conditions (including therapeutic thoraco- or', 'paracentesis) is eligible.', '25. Is pregnant or breastfeeding, or expecting to conceive or father children within the', 'projected duration of the study starting with the screening visit through 120 days after', 'the last dose of pembrolizumab or saline placebo or up to 180 days after last dose of', 'chemotherapeutic agents, whichever is later.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}